This live activity will review newly approved and investigational agents and combinations of agents that may improve outcomes for patients with relapsed, refractory follicular lymphoma (FL). Traditionally, FL has been associated with the development of aggressive disease and poor outcomes for many patients. The ongoing development of new compounds with unique mechanisms of action extends the available treatment options for patients across all lines of therapy, with an emphasis on personalization of care.

This live activity will cover the treatment and management of patients with bladder cancer.

This live activity will cover the treatment and management of patients with metastatic, hormone receptor-positive, HER-2 negative breast cancer.

This live activity will cover the treatment and management of patients with advanced gastric cancer (GC) and gastroesophageal junction cancer.

This live activity is focused on the care of patients with early HER2-positive breast cancer.

This live activity will cover the treatment and management of patients with metastatic, hormone receptor-positive, HER-2 negative breast cancer.

This CME initiative is designed to meet the educational needs of urologists, medical oncologists, oncology nurses, and other health care providers involved in the treatment of patients with prostate cancer.

This live activity will cover the treatment and management of patients with advanced gastric cancer (GC) and gastroesophageal junction cancer.

This live activity will cover the treatment and management of patients with advanced gastric cancer (GC) and gastroesophageal junction cancer.

This live activity will cover the treatment and management of patients with advanced gastric cancer (GC) and gastroesophageal junction cancer.

This case-based live activity will cover the treatment and management of patients with multiple sclerosis (MS).

This live activity will cover the treatment and management of patients with advanced gastric cancer (GC) and gastroesophageal junction cancer.